Cost Effectiveness Standard: Drugs Should Be “Innocent Until Proven Guilty”
Executive Summary
Policies governing evidence-based medicine should presume that new drugs or devices are cost effective until comparative studies prove otherwise, AstraZeneca Director-Strategic Planning & Business Development Kim Slocum said during an April 27 1"Drug & Device Dialogue" audio conference sponsored by F-D-C Reports and Polidais
You may also be interested in...
E-Prescribing To Improve Postmarketing Studies, CMS’ McClellan Predicts
Electronic prescribing systems can facilitate more efficient postmarketing clinical studies, CMS Administrator Mark McClellan said April 14
Outcomes Research Is Alternative To Focus On Cost, AstraZeneca Exec Says
The pharmaceutical industry must be actively involved in determining health care outcomes or risk having the focus remain solely on drug costs, AstraZeneca Strategic Planning & Business Development Director Kim Slocum said during the World Health Care Congress Jan. 27 in Washington, D.C
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011